Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies
| Autor: | Macarena Rus, Antonio García-Ruiz, Nuria García-Agua Soler, Guillermo Izquierdo |
|---|---|
| Přispěvatelé: | [Izquierdo,G, Rus,M] Department of Neurology, Hospital Universitario Virgen Macarena, Seville, Spain. [García-Agua Soler,N, García-Ruiz,AJ] Health Economics and Rational Drug Use, School of Medicine, University of Málaga, Málaga, Spain. [García-Ruiz,AJ] Department of Pharmacology and Clinical Therapeutics, School of Medicine, University of Málaga, Málaga, Spain., This work was funded by Teva Pharma S.L.U. Partial financial support was also provided by Asociacion Neuroinvest. |
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Male
Diseases::Pathological Conditions Signs and Symptoms::Pathologic Processes::Disease Attributes::Recurrence [Medical Subject Headings] Calidad de vida Effectiveness Clinical practice Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] Behavioral Neuroscience Disability Evaluation Glatiramer acetate Clinical endpoint Secondary Prevention Medicine Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Odds Ratio [Medical Subject Headings] Original Research Diseases::Pathological Conditions Signs and Symptoms::Pathologic Processes::Disease Attributes::Chronic Disease [Medical Subject Headings] treatment Hazard ratio Middle Aged Antirheumatic Agents Cohort Disease Progression Female medicine.drug Cohort study Adult medicine.medical_specialty Multiple Sclerosis Recurrencia effectiveness Oportunidad relativa Diseases::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases CNS::Multiple Sclerosis [Medical Subject Headings] Multiple sclerosis Disciplines and Occupations::Social Sciences::Quality of Life [Medical Subject Headings] Internal medicine Humans Retrospective Studies therapy Expanded Disability Status Scale Diseases::Pathological Conditions Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Progression [Medical Subject Headings] business.industry Enfermedad crónica Retrospective cohort study Odds ratio Glatiramer Acetate Patient Outcome Assessment Treatment Spain Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies [Medical Subject Headings] Physical therapy Quality of Life Therapy business |
| Zdroj: | Brain and Behavior |
| Popis: | Journal Article; Research Support, Non-U.S. Gov't; OBJECTIVE To assess the effectiveness of glatiramer acetate (GA) compared to other multiple sclerosis (MS) therapies in routine clinical practice. MATERIALS AND METHODS Observational cohort study carried out in MS patients treated with GA (GA cohort) or other MS therapies -switched from GA- (non-GA cohort). Study data were obtained through review of our MS patient database. The primary endpoint was the Expanded Disability Status Scale (EDSS) scores reached at the end of treatment/last check-up. RESULTS A total of 180 patients were included: GA cohort n = 120, non-GA cohort n = 60. Patients in the GA cohort showed better EDSS scores at the end of treatment/last check-up (mean ± SD, 2.8 ± 1.8 vs. 3.9 ± 2.2; P = 0.001) and were 1.65 times more likely to show better EDSS scores compared to the non-GA cohort (odds ratio, 0.606; 95%CI, 0.436-0.843; P = 0.003). Patients in the GA cohort showed longer mean time to reach EDSS scores of 6 (209.1 [95%CI, 187.6-230.6] vs. 164.3 [95% CI, 137.0-191.6] months; P = 0.004) and slower disability progression (hazard ratio, 0.415 [95%CI, 0.286-0.603]; P < 0.001). The annualized relapse rate was lower in the GA cohort (mean ± SD, 0.5 ± 0.5 vs. 0.8 ± 0.5; P = 0.001) and patients' quality of life was improved in this study cohort compared to the non-GA cohort (mean ± SD, 0.7 ± 0.1 vs. 0.6 ± 0.2; P = 0.01). CONCLUSIONS GA may slow down the progression of EDSS scores to a greater extent than other MS therapies, as well as achieving a greater reduction in relapses and a greater improvement in patients' quality of life. Switching from GA to other MS therapies has not proved to entail a better response to treatment. Yes |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|